A M Eggermont
Overview
Explore the profile of A M Eggermont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
192
Citations
1717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacquelot N, Roberti M, Enot D, Rusakiewicz S, Ternes N, Jegou S, et al.
Nat Commun
. 2017 Sep;
8(1):592.
PMID: 28928380
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors...
2.
Ribero S, Longo C, Dika E, Fortes C, Pasquali S, Nagore E, et al.
J Eur Acad Dermatol Venereol
. 2016 May;
31(1):65-69.
PMID: 27231086
Background: Management of melanoma during pregnancy can be extremely challenging. The reported incidence of melanoma in pregnancy ranges from 2.8 to 5.0 per 100 000 pregnancies. There are no guidelines...
3.
van Gool A, Kruit W, Cornelissen J, Berk L, Eggermont A, Bannink M
Acta Neuropsychiatr
. 2016 Mar;
11(4):120-4.
PMID: 26976539
Immunotherapy with interferon-alfa has become standard therapy in selected patients with viral hepatitis and chronic myelogenous leukemia. In addition, it is used in a variety of other diseases, both as...
4.
Ayez N, van der Stok E, Grunhagen D, Rothbarth J, van Meerten E, Eggermont A, et al.
Eur J Surg Oncol
. 2015 May;
41(7):859-67.
PMID: 25979624
Aim: The combination of surgery and chemotherapy (CTx) is increasingly accepted as an effective treatment for patients with colorectal liver metastases (CRLM). However, controversy exists whether all patients with resectable...
5.
Rodon J, Soria J, Berger R, Batist G, Tsimberidou A, Bresson C, et al.
Ann Oncol
. 2015 Apr;
26(8):1791-8.
PMID: 25908602
Advances in 'omics' technology and targeted therapeutic molecules are together driving the incorporation of molecular-based diagnostics into the care of patients with cancer. There is an urgent need to assess...
6.
van der Pool A, de Wilt J, Lalmahomed Z, Eggermont A, Ijzermans J, Verhoef C
Br J Surg
. 2010 Jan;
97(3):383-90.
PMID: 20101594
Background: This study evaluated the outcome of patients treated for rectal cancer and synchronous hepatic metastases in the era of effective induction radiotherapy and chemotherapy. Methods: All patients undergoing surgical...
7.
Punt C, Eggermont A
Ann Oncol
. 2002 Feb;
12(12):1663-6.
PMID: 11843241
Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNalpha) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these...
8.
9.
Eggermont A
Eur J Cancer
. 2001 Oct;
37(17):2147-53.
PMID: 11677100
Interferon-alpha (IFNalpha) is a pleiotropic cytokine with various direct and indirect inflammatory response modulating activities. Some of these activities may have direct or indirect antitumour effects. For such a wide...
10.
Lejeune F, Kroon B, Di Filippo F, Hoekstra H, Santinami M, Lienard D, et al.
Surg Oncol Clin N Am
. 2001 Oct;
10(4):821-32, ix.
PMID: 11641093
Isolated limb perfusion (ILP) is a method of cancer treatment allowing the administration of high doses of anticancer agents in a limb surgically isolated from systemic circulation. By using continuous...